Search Results for "anaphylaxis"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for anaphylaxis. Results 51 to 60 of 63 total matches.

Two New Oral Testosterone Products for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022  (Issue 1662)
and anaphylaxis. 7. Implant 2 pellets for each 25 mg of testosterone propionate required weekly. 8. Applied ...
The FDA has approved two new oral formulations of testosterone undecanoate — Kyzatrex (Marius) and Tlando (Antares) — for treatment of males with a deficiency of endogenous testosterone due to conditions such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury caused by tumors, trauma, or radiation. Jatenzo, another oral testosterone undecanoate formulation, was approved for the same indication in 2019. No testosterone products are approved for treatment of low testosterone levels due solely to...
Med Lett Drugs Ther. 2022 Oct 31;64(1662):172-4 |  Show IntroductionHide Introduction

Comparison Table: Some Drugs for Gout (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
efficacy and may cause infusion reactions and a high risk (~5%) of anaphylaxis Contraindicated for use ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9   doi:10.58347/tml.2023.1688c |  Show IntroductionHide Introduction

IV Artesunate for Severe Malaria

   
The Medical Letter on Drugs and Therapeutics • Aug 10, 2020  (Issue 1604)
with hypersensitivity reactions, including anaphylaxis, in ~1 in 3000 treated individuals. Cases of severe ...
Artesunate for injection (Amivas LLC), a semi-synthetic artemisinin derivative, is now approved by the FDA for initial (induction) treatment of severe malaria in children and adults. It has been available from the CDC on a compassionate use basis since 2007. Artemether/lumefantrine (Coartem), another artemisinin-based drug, was approved earlier for oral treatment of uncomplicated Plasmodium falciparum malaria. IV artesunate is now the only FDA-approved injectable antimalarial drug available in the US; IV quinidine has been discontinued.
Med Lett Drugs Ther. 2020 Aug 10;62(1604):121-4 |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
to persons with a history of anaphylaxis caused by neomycin (M-M-R II and Priorix) or gelatin (M-M-R II ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Drugs for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021  (Issue 1637)
, and hepatotoxicity have been reported. Anaphylaxis, Stevens-Johnson syndrome, weight loss, interstitial lung ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of adults in the US; it is about 2.5 times more common in women than in men. Guidelines for treatment of RA from the American College of Rheumatology were recently updated. The goal of treatment is to minimize disease activity and prevent irreversible joint damage.
Med Lett Drugs Ther. 2021 Nov 15;63(1637):177-84 |  Show IntroductionHide Introduction

Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
reactions, including anaphylaxis and angioedema, have also been reported. The most common adverse effects ...
The subcutaneously injected interleukin-13 (IL-13) antagonist tralokinumab-ldrm (Adbry – Leo) and the oral Janus kinase (JAK) inhibitors abrocitinib (Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie) have been approved by the FDA for treatment of moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5   doi:10.58347/tml.2023.1673b |  Show IntroductionHide Introduction

Antiviral Drugs for Seasonal Influenza for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2024  (Issue 1717)
of influenza itself.47 Hypersensitivity reactions, including anaphylaxis, have been reported ...
Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in persons at increased risk for influenza complications (see Table 1). Updated information on influenza activity and antiviral resistance is available from the CDC at cdc.gov/flu.
Med Lett Drugs Ther. 2024 Dec 9;66(1717):193-8   doi:10.58347/tml.2024.1717a |  Show IntroductionHide Introduction

Drugs for Gout

   
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023  (Issue 1688)
and may be responsible for the relatively common infusion reactions and high risk of anaphylaxis (~5%) associated ...
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75   doi:10.58347/tml.2023.1688a |  Show IntroductionHide Introduction

Drugs for Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Mar 22, 2021  (Issue 1620)
, diarrhea, 14,826.80 Tecfidera (Biogen) lymphopenia, infections, anaphylaxis, 99,310.70 angioedema ...
Most patients with multiple sclerosis (MS) present with the relapsing-remitting form of the disease. Pharmacologic treatment usually includes a disease-modifying drug, corticosteroids for acute exacerbations, and other drugs for managing symptoms such as fatigue, depression, and pain. Early use of disease-modifying therapy has improved clinical outcomes.
Med Lett Drugs Ther. 2021 Mar 22;63(1620):42-8 |  Show IntroductionHide Introduction

Drugs for Inflammatory Bowel Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023  (Issue 1680)
immunosuppression. Hypersensitivity reactions, including anaphylaxis, have been reported with vedolizumab. Severe ...
Ulcerative colitis (UC) and Crohn's disease (CD), referred to collectively as inflammatory bowel disease (IBD), are chronic immune-mediated inflammatory conditions. Guidelines for treatment of UC and CD have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12   doi:10.58347/tml.2023.1680a |  Show IntroductionHide Introduction